Symbols

Beyond Air Soars 5.42% on Premier Contract

Generated by AI AgentAinvest Pre-Market Radar

Tuesday, Jul 22, 2025 7:50 am ET1min read

Aime Summary

- Beyond Air's stock jumped 5.42% pre-market after securing a Premier, Inc. contract covering two-thirds of U.S. hospitals.

- The deal accelerates adoption of its cylinder-free nitric oxide system to enhance hospital efficiency and patient outcomes.

- FDA medical device designation for LungFit validates the company's innovative approach to critical healthcare solutions.

On July 22, 2025, Beyond Air's stock surged by 5.42% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Beyond Air has secured a premier contract with Premier, Inc., granting the company access to two-thirds of the U.S. hospital market. This agreement is expected to streamline the adoption process for Beyond Air's innovative cylinder-free nitric oxide system, which is designed to improve patient outcomes and operational efficiency in hospitals.

Beyond Air's LungFit, a cylinder-free, phasic flow generator and delivery system, has been designated as a medical device by the U.S. Food and Drug Administration (FDA). This designation underscores the company's commitment to developing cutting-edge medical technologies that address critical healthcare needs.

Ainvest Pre-Market Radar

Get the scoop on pre-market movers and shakers in the US stock market.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue